XML 15 R2.htm IDEA: XBRL DOCUMENT v3.23.4
Consolidated Balance Sheets - USD ($)
Sep. 30, 2023
Sep. 30, 2022
Current Assets:    
Cash and cash equivalents $ 26,480,928 $ 41,711,690
Prepaid expenses 7,889,506 2,852,580
Total Current Assets 34,370,434 44,564,270
Property and equipment, net 1,432 4,100
Operating lease right-of-use asset, net 454,426 646,074
Other Assets:    
Deposits 38,062 38,062
In-process research and development 59,400,000 59,400,000
Goodwill 9,346,796 9,346,796
Total Other Assets 68,784,858 68,784,858
Total Assets 103,611,150 113,999,302
Current Liabilities:    
Accounts payable 2,927,334 1,165,378
Accrued expenses 476,300 1,405,394
Accrued compensation 2,156,983 1,762,251
Operating lease liability 218,380 196,989
Total Current Liabilities 5,778,997 4,530,012
Deferred tax liability 6,137,800 5,561,800
Operating lease liability – non current 262,865 481,245
Total Liabilities 12,179,662 10,573,057
Commitments and Contingencies
Stockholders’ Equity:    
Preferred stock - $0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding
Common stock - $0.001 par value; 400,000,000 shares authorized; 158,857,798 and 146,211,130 shares issued and outstanding at September 30, 2023 and 2022, respectively 158,858 146,211
Additional paid-in capital 252,903,629 232,368,121
Accumulated deficit (162,231,379) (129,688,467)
Total Citius Pharmaceuticals, Inc. Stockholders’ Equity 90,831,108 102,825,865
Non-controlling interest 600,380 600,380
Total Equity 91,431,488 103,426,245
Total Liabilities and Equity $ 103,611,150 $ 113,999,302